DEF: IMUNON Seeks Shareholder Approval for Reverse Stock Split, Capital Raise, and Increased Share Authorization Amidst Nasdaq Delisting Threat

IMUNON, INC. is calling for its annual stockholder meeting on July 11, 2025, to vote on critical proposals including a reverse stock split, a significant increase in authorized shares, and the approval of shares underlying recent warrants, all aimed at addressing Nasdaq listing deficiencies and securing future funding.

Summary

• IMUNON, INC. will hold its Annual Meeting of Stockholders virtually on Friday, July 11, 2025, at 10:00 A.M. Eastern Time.
• Stockholders will vote on the re-election of two Class III Directors, Dr. Donald P. Braun and Mr. Michael H. Tardugno, whose terms would expire in 2028.
• The company seeks ratification of WithumSmith+Brown PC as its independent registered public accounting firm for the fiscal year ending December 31, 2025.
• A non-binding advisory vote will be held to approve the 2024 executive compensation for Named Executive Officers.
• Stockholder approval is requested for the issuance of shares underlying warrants from a May 23, 2025, private placement, which included 2,777,779 common shares, 4,444,444 pre-funded warrants, and 14,444,446 common warrants, plus 361,111 placement agent warrants, to comply with Nasdaq Listing Rule 5635(d).
• The company proposes an amendment to its Certificate of Incorporation to increase authorized common stock from 112,500,000 shares to 350,000,000 shares.
• A reverse stock split at a ratio between 1:5 and 1:18 is proposed, at the Board's discretion, primarily to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• An amendment to the IMUNON, INC. 2018 Stock Incentive Plan is proposed to increase the aggregate number of shares available for awards by 2,000,000, bringing the new limit to 3,970,000 shares.
• Stockholders will also vote on the approval of any adjournment or postponement of the Annual Meeting, if necessary, to solicit additional proxies.

Sentiment

Score: 3

Explanation: The company is facing significant financial distress, evidenced by low cash reserves, persistent net losses, and an imminent Nasdaq delisting threat. While management is taking steps (reverse split, capital raise) to address these issues, these actions inherently involve substantial shareholder dilution and reflect a precarious operational environment. The write-off of a related party investment further underscores financial challenges. The sentiment is negative due to the severity of the challenges, despite proactive measures.

Positives

• The company is actively pursuing measures (reverse stock split, capital raise approval) to regain compliance with Nasdaq listing requirements and avoid delisting.
• The virtual meeting format is adopted to expand access, improve communications, and reduce costs for stockholders and the company.
• The company has robust internal processes and a strong internal control environment for risk management, with regular communication to the Board.
• IMUNON maintains strong corporate governance practices, including independent directors, committee charters, stock ownership guidelines, an anti-hedging/pledging policy, an executive compensation clawback policy, and annual management talent/succession reviews.
• The company's historical equity usage (average three-year run rate of 6.6%) compares favorably to the non-Russell 3000 Index (Pharmaceuticals, Biotechnology & Life Science) mean run rate of 8.6%.

Negatives

• The company received a delisting notice from Nasdaq on November 26, 2024, for failing to meet the minimum bid price requirement of $1.00 per share.
• IMUNON was determined ineligible for a further 180-calendar-day extension to regain compliance due to not meeting the minimum stockholders' equity initial listing requirement of $5,000,000, leading to a delisting determination letter on May 28, 2025.
• The company reported a net loss of $18,620,242 for the fiscal year ended December 31, 2024, following a net loss of $19,514,977 in 2023 and $35,465,260 in 2022, indicating ongoing operational losses.
• Cash and cash equivalents significantly decreased from $5.9 million on December 31, 2024, to $2.9 million on March 31, 2025, highlighting liquidity concerns.
• The proposed increase in authorized shares and the issuance of shares underlying warrants will result in significant dilution for existing stockholders.
• The company incurred a complete write-off of a $375,000 convertible note and related warrants from an investment in Transomic Technologies, Inc. in December 2023 due to its dissolution.
• Two Section 16(a) reports for insiders (Stacy Lindborg and Donald Braun) were not filed in a timely manner.

Risks

• Risk of delisting from The Nasdaq Capital Market if the company fails to regain compliance with listing requirements, which could adversely affect liquidity, trading volume, and stock price.
• Potential inability to fund operations if the approximately $6.7 million in gross proceeds from warrant exercises are not realized due to lack of stockholder approval for the Issuance Proposal.
• Significant dilution of existing stockholders' percentage equity ownership and potential negative impact on common stock market price if additional authorized shares are issued in future financings or strategic transactions.
• The reverse stock split may not lead to a sustained increase in bid price or may result in reduced liquidity and trading volume.
• Risk of not being able to recruit, retain, and reward key employees without an increase in available shares for equity-based compensation programs.
• The company's substantial operating losses from research and development programs and clinical trials indicate significant future capital requirements.

Future Outlook

IMUNON anticipates substantial future capital requirements to continue its research and development activities and advance its drug candidates through various development stages. The company aims to regain and maintain compliance with Nasdaq listing rules, particularly the minimum bid price, through a proposed reverse stock split. The increase in authorized shares and the amendment to the stock incentive plan are intended to provide flexibility for future financings, strategic transactions, and to attract and retain key employees, which are deemed essential for the company's ongoing success and business plan execution.

Management Comments

• "We have adopted a virtual meeting format to expand access to the meeting, improve communications and impose lower costs on our stockholders, the Company and the environment. We believe virtual meetings enable increased stockholder participation from locations around the world."
• "Our Board of Directors believes that it is important to select our Chairman of the Board and our Chief Executive Officer in the manner it considers in our best interests."
• "Our Board of Directors recognizes that it is neither possible nor prudent to eliminate all risk. Indeed, purposeful and appropriate risk-taking is essential for us to be competitive and to achieve our business objectives."
• "We believe that the Private Placement, which yielded gross proceeds of approximately $3.25 million, was necessary in light of our cash and funding requirements at the time."
• "The Board believes that a Reverse Stock Split is a potentially effective means for the Company to regain and maintain compliance with Nasdaq Marketplace Rules and to avoid, or at least mitigate, the likely adverse consequences of common stock being delisted from The Nasdaq Capital Market by producing the immediate effect of increasing the bid price of our common stock."
• "The Board of Directors believes that the proposed 2018 Plan amendment is essential for our ongoing success and our ability to recruit, retain and reward key employees."
• "If stockholders do not approve this 2018 Plan amendment, the current share limit under, and other terms and conditions of the 2018 Plan, will continue in effect (to be adjusted by the Reverse Stock Split, if approved and implemented)."

Industry Context

IMUNON operates as a clinical-stage biotechnology company, a sector characterized by high research and development costs, significant capital requirements, and often, sustained operating losses. The company's current challenges, including low cash reserves and a Nasdaq delisting notice due to a sub-$1.00 stock price, are common for smaller biotech firms struggling to advance drug candidates through costly clinical trials without consistent revenue streams. The proposed reverse stock split and capital raise initiatives reflect a typical strategy for such companies to maintain public listing and secure necessary funding for continued development in a highly competitive and capital-intensive industry.

Comparison to Industry Standards

• IMUNON's average three-year equity usage run rate of 6.6% as a percentage of weighted common shares outstanding compares favorably to the non-Russell 3000 Index (Pharmaceuticals, Biotechnology & Life Science) mean run rate of 8.6% for the same period, suggesting a relatively efficient use of equity for compensation compared to industry peers.
• The company's reliance on equity-based compensation to attract and retain key employees is a standard practice in the high-risk biotechnology industry, aligning employee interests with long-term shareholder value, similar to other development-stage biopharma companies.
• The need for a reverse stock split to maintain Nasdaq listing is a common occurrence for small-cap biotechnology companies whose stock prices often fluctuate below the minimum bid requirement due to market volatility, clinical trial outcomes, and lack of commercial products, similar to many emerging biopharmaceutical firms.

Management Changes

Corporate Governance

Related Party Transactions

• On November 16, 2022, the Company purchased $375,000 of convertible notes and warrants from Transomic Technologies, Inc. (Transomic). IMUNON's Executive Chairman, Michael Tardugno, was appointed to Transomic's Board of Directors as a result of this investment.
• In December 2023, Transomic filed a formal certificate of dissolution, leading to a complete write-off of IMUNON's convertible note and related warrants.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the proposed increase in authorized shares and the exercise of warrants. The reverse stock split aims to prevent delisting, which would negatively impact liquidity and trading, but its long-term effect on stock price is uncertain. The write-off of the Transomic investment represents a loss of shareholder capital.
• **Employees**: The proposed amendment to the 2018 Stock Incentive Plan is crucial for attracting, retaining, and rewarding key employees through equity-based compensation, which is vital for a clinical-stage biotech company.
• **Management**: Executive compensation is subject to a non-binding advisory vote and a clawback policy, increasing accountability. Management's ability to execute the business plan is highly dependent on securing additional capital and maintaining Nasdaq listing.
• **Creditors**: The company's low cash reserves and ongoing net losses indicate potential challenges in meeting future obligations, though the capital raise efforts aim to mitigate this.

Next Steps

• Stockholders to vote on proposals at the Annual Meeting on July 11, 2025.
• Board of Directors to determine the exact ratio for the reverse stock split (between 1:5 and 1:18) if approved by stockholders.
• Company to file the Certificate of Amendment for the Authorized Share Increase and/or Reverse Stock Split with the Delaware Secretary of State if approved.
• Company to continue appealing Nasdaq's delisting determination to a Nasdaq Hearings Panel.
• Company to potentially receive additional capital (up to $6.7 million) upon the exercise of warrants, contingent on stockholder approval of the Issuance Proposal.
• Company to call a meeting every 90 days to seek Stockholder Approval for the Issuance Proposal if not obtained at the Annual Meeting, until approval is obtained or warrants are no longer outstanding.

Key Dates

Recommendation

Keywords

SEC Filing, Proxy Statement, Annual Meeting, Reverse Stock Split, Authorized Share Increase, Nasdaq Delisting, Capital Raise, Warrants, Stock Incentive Plan, Executive Compensation, Corporate Governance, Biotechnology, Clinical Stage, IMUNON